Prothena Corporation plc
NASDAQ:PRTABiotechnology
+$0.33 today
- Market cap
- $424.15M
- Beta
- -0.32
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.81
Volume 0.60M
Average 0.51M
Returns on capital
Prothena Corporation plc management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-87.0%
avg -34.9%
ROIC
-63.9%
avg -28.1%
ROA
-74.7%
avg -26.6%
Analysis
ROIC is currently the strongest return metric at -63.9% versus its period average of -28.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Gene G. Kinney | President, Chief Executive Officer & Director | USD 1.12M | 57 | 0 | <0.01% |
Tran Nguyen | Chief Financial Officer | USD 916.33K | 52 | 0 | <0.01% |
Brandon S. Smith | Chief Operating Officer | USD 826.82K | 51 | 0 | <0.01% |
Chad Swanson | Chief Development Officer | USD 739.08K | — | — | — |
Wagner Zago | Chief Scientific Officer | USD 735.66K | 53 | — | — |
Michael J. Isaacs | General Counsel & Corporate Secretary | — | — | — | — |
Annie Evans Kingston | Chief Strategy Officer | — | — | — | — |
Karin L. Walker | Chief Accounting Officer & Controller | — | 63 | 0 | <0.01% |
Phillip Dolan | Sr. Director & Head of Exploratory Research | — | — | — | — |
Mark C. Johnson | Vice President of Investor Relations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 28, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
20
$13.27M
Sells
2
$135,974.78
Net Transaction Value
+$13.13M
Net buying
Most Active
SCULLY WILLIAM P
20 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 9, 26Nov 9, 2026 | SCULLY WILLIAM P Direct | Buy | $1.2M$1,194,158.00 |
| Oct 23, 26Oct 23, 2026 | SCULLY WILLIAM P Direct | Buy | $403.5K$403,525.00 |
| Oct 22, 26Oct 22, 2026 | SCULLY WILLIAM P Direct | Buy | $818.5K$818,520.00 |
| Oct 14, 26Oct 14, 2026 | SCULLY WILLIAM P Direct | Buy | $84.6K$84,569.00 |
| Oct 13, 26Oct 13, 2026 | SCULLY WILLIAM P Direct | Buy | $835.5K$835,480.00 |
| Oct 8, 26Oct 8, 2026 | SCULLY WILLIAM P Indirect | Buy | $770.9K$770,904.00 |
| Oct 7, 26Oct 7, 2026 | SCULLY WILLIAM P Indirect | Buy | $1.1M$1,050,150.00 |
| Oct 2, 26Oct 2, 2026 | SCULLY WILLIAM P Indirect | Buy | $857.2K$857,240.00 |
| Sep 29, 26Sep 29, 2026 | SCULLY WILLIAM P Indirect | Buy | $1.4M$1,405,674.00 |
| Sep 28, 26Sep 28, 2026 | SCULLY WILLIAM P Indirect | Buy | $889.9K$889,872.30 |
1–10 of 22
Summary
Insiders reported 20 buys worth $13.27M and 2 sells worth $135,974.78 over the last 12 months. That adds up to net buying of $13.13M. SCULLY WILLIAM P was the most active insider with 20 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -43.6% | +89.4% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -43.6% over three years. Forward estimates point to Revenue at +89.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Prothena Corporation plc compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about PRTA's management, answered from reported figures.
Who manages PRTA?
Prothena Corporation plc (PRTA) lists 10 active executives. The top listed executive is Chad Swanson, Chief Development Officer.
Are PRTA insiders buying or selling?
Recent insider activity shows net buying of $32.26M.
Continue the stock analysis
Jump to another research area for this company.